Norris Financial Group’s VanEck Biotech ETF BBH Stock Holding History

Norris Financial Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,675	Closed	-$1.24M	–	68
2022 Q1	$1.24M	Buy	+7,675	New	+$1.24M	0.75%	31

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Norris Financial Group's BBH Position: Q2 2022 in Review

Norris Financial Group sold out of VanEck Biotech ETF (BBH) in Q2 2022, closing a stake of 7,675 shares — an estimated $1.24M sold.

Norris Financial Group first reported a position in BBH in Q1 2022 and held it in 1 quarter. The position peaked at $1.24M in Q1 2022. 108 funds tracked by Wall St. Rank hold BBH as of Q2 2022.

Norris Financial Group reported no remaining VanEck Biotech ETF position as of Q2 2022 after selling out during the quarter.
Norris Financial Group sold 7,675 VanEck Biotech ETF shares in Q2 2022, an estimated $1.24M.
Norris Financial Group first reported a position in VanEck Biotech ETF in Q1 2022 and held it in 1 quarter.
Norris Financial Group's VanEck Biotech ETF position peaked at $1.24M in Q1 2022.
108 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2022.

Based on Norris Financial Group's 13F filing for Q2 2022, filed 20 May 2026.